PR Newswire Clinical TrialsOriginal article
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
ConferenceIvonescimabPositive
AI Analysis
Summary
Akeso announced that ivonescimab Phase III overall survival data in first-line biliary tract cancer has been selected as a late-breaking abstract for ESMO 2026, with nearly 30 Akeso studies to be presented at the conference.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Phase III overall survival data selected as late-breaking abstract at ESMO 2026
Importance:6/10
Sentiment:
0.60
Ivonescimabbiliary tract cancerPhase 3ESMO 2026late-breaking abstractbispecific antibodyoverall survival
Read the original article
Published by PR Newswire Clinical Trials on September 21, 2026 11:46 PM